Hernández, M. (M.)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
8 results
Search Results
Now showing 1 - 8 of 8
- Tratamiento profiláctico de la enfermedad tromboembólica en el paciente quirúrgico(Universidad de Navarra, 1987) Paramo, J.A. (José Antonio); Hernández, M. (M.); Rocha, E. (Eduardo); Fernandez, J. (Javier); Cuesta, B. (Braulia); Aranda, A. (Alejandro)
- Utilización de células madre en terapia regenerativa cardíaca(Servicio de Publicaciones de la Universidad de Navarra, 2002) Herreros, J. (Jesús); Hernández, M. (M.); Rifon, J. J. (Jose J.); Rocha, E. (Eduardo); Cosin, J. (Juan); Inoges, S. (Susana); Perez-Calvo, J. (Javier); Rabago, G. (Gregorio); Panizo, A. (Ángel); Prosper-Cardoso, F. (Felipe); Perez, A. (Ana)One of the most important challenges in modern medicine is the use of stem cells for the treatment of human disease such as diabetes, Parkinson ́s disease or isquemic cardiomyopathy. A number of problems need to be solved before stem cells can be applied clinically. In this paper we will review some concepts related to the potential of stem cells, focusing on adult stem cells as they have recently been described by the group of Catherine Verfaillie. We will also present our initial clinical results using adult stem cells for cardiac regenerative therapy. In the studies mentioned above, autologous muscle stem cells (satelite cells) were infused directly in the periphery of the scar tissue of the infarct. We describe the technique for ex vivo expansion and purification of muscle stem cells.
- Angiotensin converting enzyme inhibition prevents polyploidization of cardiomyocytes in spontaneously hypertensive rats with left ventricular hypertrophy(John Wiley and Sons, 1995) Hernández, M. (M.); Diez-Martinez, J. (Javier); Panizo, A. (Ángel); Pardo-Mindan, F.J. (Francisco Javier); Cenarruzabeitia, E. (Edurne); Sola, J.J. (Jesús Javier)Polyploidization of cardiomyocyte nuclei is a physiological phenomenon that increases in pathological conditions such as myocardial hypertrophy. The purpose of this study was to evaluate the potential benefit of the angiotensin converting enzyme (ACE) inhibitor quinapril in reversing the polyploidization of cardiomyocyte nuclei in spontaneously hypertensive rats (SHR) with established left ventricular hypertrophy (LVH). Sixteen week-old male SHR were treated with oral quinapril (average dose 10 mg/kg per day) for 20 weeks. Sixteen- and 36-week-old untreated SHR and 16- and 36-week-old normotensive Wistar-Kyoto (WKY) rats were used as controls. Nuclear polyploidization was determined by DNA flow cytometry of frozen tissues from the left ventricle, at least 20 000 nuclei being measured in each sample. The rates of tetraploidy in the 16- and 36-week-old SHR groups were 2·8 per cent (range 2·16-3 per cent) and 5·4 per cent (range 4·9–5·9 per cent), respectively. Treated SHR had a similar rate of DNA tetraploidy to the 16- and 36-week-old WKY rat groups: 1·8 per cent (range 1·5–2·3 per cent), 1·55 per cent (range 1·5–1·6 per cent), and 1·5 per cent (range 1·4–1·6 per cent), respectively. The differences in the percentage of tetraploid cardiomyocytes between the SHR untreated groups and the SHR treated group were statistically significant (P<0·05). Regression of LVH and normalization of blood pressure were observed in treated rats. These results indicate that DNA tetraploidy in the myocardium of SHR increases with hypertrophy and decreases on quinapril treatment. It is suggested that ACE inhibition modifies nuclear processes involved in myocyte growth in arterial hypertension.
- Púrpura trombótica trombocitopénica: tratamiento con plasmaferesis, plasma fresco, antiagregantes plaquetares y corticoides(Universidad de Navarra, 1987) Paramo, J.A. (José Antonio); Hernández, M. (M.); Rocha, E. (Eduardo); Cuesta, B. (Braulia); Gomez, C. (C.); Viteri, C. (César)
- Indications for bone marrow transplantation(Ediciones Universidad de Navarra, 1994) Hernández, M. (M.); Rifon, J. J. (Jose J.); Rocha, E. (Eduardo); Panizo, C. (Carlos); Hermida, J. (José); Cuesta, B. (Braulia); Prosper-Cardoso, F. (Felipe)
- Inhibidores de la coagulación en pacientes neoplásicos(Elsevier, 1989) Paramo, J.A. (José Antonio); Hernández, M. (M.); Rifon, J. J. (Jose J.); Rocha, E. (Eduardo); Fernandez, J. (Javier); Cuesta, B. (Braulia); Paloma, M.J. (María José)
- Papel del sistema fibrinolítico en la trombosis(Universidad de Navarra, 1987) Paramo, J.A. (José Antonio); Hernández, M. (M.); Rocha, E. (Eduardo); Fernandez, J. (Javier); Cuesta, B. (Braulia); Aranda, A. (Alejandro)
- Clotting activation and impairment of fibrinolysis in malignancy(Elsevier, 1989) Paramo, J.A. (José Antonio); Hernández, M. (M.); Fernandez, F.J. (Francisco J.); Rifon, J. J. (Jose J.); Rocha, E. (Eduardo); Cuesta, B. (Braulia); Paloma, M.J. (María José)Different coagulation and fibrinolysis parameters were investigated in 149 patients with metastatic and non-metastatic tumours and results were compared with those obtained in a healthy population. Results showed a significant increase of thrombin-antithrombin complexes, fibrinopeptide A (FPA) and fibrin monomers in the group of patients (p less than 0.001). There was also a significant prolongation of euglobulin lysis time (p less than 0.005) and an increase of plasminogen activator inhibitor activity (p less than 0.0001), fibrinogen degradation products (p less than 0.001), and D-dimer (p less than 0.05) in the group of patients as compared to controls; FPA levels were also increased in patients with metastases (p less than 0.005). This study demonstrates clotting activation, at the level of fibrinogen to fibrin conversion, and impairment of fibrinolysis in patients with malignancy.